Международный журнал воспаления, рака и интегративной терапии

Абстрактный

A Delphi Study Yielded Consensus Views on Advanced Breast Cancer Education Curriculum for Cancer Nurses

Elizabeth Dury

Background: For people living with advanced breast cancer, specialist nursing care is a key indicator of quality care. However, access to and quality of advanced breast cancer nurse education programmes varies [1].
Objectives: The purpose of this study is to define the topics that will be included in an international curriculum for an advanced breast cancer education programme.
Methods: A modified four- round Delphi study was accepted with experts by profession and experience in advanced bone cancer. Thirty- four motifs related to advanced bone cancer and six online tutoring and literacy styles werepreselected following a methodical review. Between September 2021 and March 2022, the expert panel determined the significance of motifs for addition in the education programme. Consensus was defined by at least 80 agreement on the loftiest three points on a 9- point Likert scale.
Results: A aggregate of 31 experts shared in rounds 1 – 3 of this study, and 156 experts by profession and experience shared in an fresh fourth round, including people living with advanced bone cancer (n = 72, 46), healthcare professionals (n = 46, 29), family members or caregivers of a person diagnosed with advanced bone cancer (n = 30, 19) and advocacy professionals working in the area of advanced bone cancer (n = 8, 5). In round 4, 36 motifs and five of six literacy styles reached agreement [2].
Conclusions: The results of this study give a frame to develop education programmes in advanced bone cancer, defining the essential rudiments of class content for similar programmes. The results punctuate the need for advanced bone cancer education programmes to use multiple tutoring and literacy styles to promote nurses' understanding of person- centred probative care and the physical, psychosocial and spiritual issues endured by people living with advanced bone cancer.